Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)

Trial Profile

Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Tofacitinib (Primary) ; Anti-TNF monoclonal antibodies; Disease-modifying antirheumatics; Etanercept; Tumour necrosis factor alpha inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Mar 2021 to 26 Jan 2021.
    • 11 Jul 2017 Planned primary completion date changed from 1 Mar 2021 to 26 Jan 2021.
    • 20 Feb 2017 Planned End Date changed from 1 Feb 2020 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top